Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c, Revenues Beat

Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.02 worse than the analyst estimate of ($1.70). Revenue for the quarter came in at $24.15 million versus the consensus estimate of $22.52 million.

“The U.S. launch of Crysvita continues to be strong with the number of patients on reimbursed therapy increasing significantly this quarter and the number of unique prescribers continuing to grow steadily,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “Earlier this week we submitted the New Drug Application for UX007, which marks significant progress in bringing this important therapy to patients, and we are advancing our gene therapy platform with updates expected from the two clinical-stage programs in the third quarter.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• RBC Capital Starts Ultragenyx Pharma (RARE) at Outperform 'Given Base Business Offers Downside Protection & OI Material Upside Potential'
• HealthStream (HSTM) Tops Q1 EPS by 6c, provides guidance
• First Bank (FRBA) Tops Q1 EPS by 7c